Table 2: Annualized age-specific incidence (per 100 000 population) of invasive pneumococcal disease among adults 65 years of age and older in Ontario, 2007-2014.
| Vaccine type | Rate (per 100 000 population) by age group | |||||
|---|---|---|---|---|---|---|
| 65-74 yr | p value | 75-84 yr | p value | ≥ 85 yr | p value | |
| All types | 18.7 | Reference | 26.5 | < 0.001 | 50.3 | < 0.001 |
| PCV7 | 1.3 | Reference | 1.6 | 0.205 | 4.0 | < 0.001 |
| Additional PCV13 | 5.3 | Reference | 6.8 | 0.001 | 12.4 | < 0.001 |
| PCV13 | 6.7 | Reference | 8.5 | 0.001 | 16.5 | < 0.001 |
| Unique PPV23 | 3.7 | Reference | 4.9 | 0.001 | 9.0 | < 0.001 |
| NVP | 3.4 | Reference | 5.7 | < 0.001 | 10.6 | < 0.001 |
Note: NVP = non-vaccine preventable serotypes, PCV7 = 7-valent pneumococcal conjugate vaccine, PCV13 = 13-valent pneumococcal conjugate vaccine, PPV23 = 23-valent polysaccharide pneumococcal vaccine.